Genmab As Stock Performance
| GMAB Stock | USD 33.88 0.78 2.36% |
On a scale of 0 to 100, Genmab AS holds a performance score of 10. The company retains a Market Volatility (i.e., Beta) of 1.24, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Genmab AS will likely underperform. Please check Genmab AS's jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside , to make a quick decision on whether Genmab AS's current trending patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Genmab AS are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat conflicting basic indicators, Genmab AS sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.36 | Five Day Return 6.57 | Year To Date Return 6.47 | Ten Year Return 166.77 | All Time Return 798.67 |
Last Split Factor 5:1 | Last Split Date 2018-05-01 |
1 | Genmab AS Q3 2025 Earnings Call Transcript | 11/11/2025 |
2 | Transactions With Shares and Linked Securities in Genmab AS Made by Managerial Employees and Their Closely Associated Persons | 12/01/2025 |
3 | AS Genmab Purchases 120,752 Shares of Merus Stock | 12/19/2025 |
4 | Genmab AS Shares Gap Up - Still a Buy - MarketBeat | 12/24/2025 |
5 | Genmab ends development of late-stage oncology asset acasunlimab | 12/29/2025 |
6 | Heres Why Genmab AS Rose in Q3 | 12/31/2025 |
7 | Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference | 01/05/2026 |
8 | Genmab AS Reaches New 1-Year High Heres What Happened | 01/07/2026 |
9 | Genmab AS A Bull Case Theory | 01/15/2026 |
10 | Genmab AS Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside | 01/20/2026 |
11 | Genmab s Future Potential Underappreciated by Market | 01/22/2026 |
12 | CD137 Targeted Therapy Research Report 2026-2030 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global Regional Clinical Commercial Trends, | 01/23/2026 |
| Begin Period Cash Flow | 14.9 B | |
| Total Cashflows From Investing Activities | -9.9 B |
Genmab AS Relative Risk vs. Return Landscape
If you would invest 2,913 in Genmab AS on October 28, 2025 and sell it today you would earn a total of 475.00 from holding Genmab AS or generate 16.31% return on investment over 90 days. Genmab AS is currently generating 0.265% in daily expected returns and assumes 2.0715% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Genmab, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Genmab AS Target Price Odds to finish over Current Price
The tendency of Genmab Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 33.88 | 90 days | 33.88 | about 6.68 |
Based on a normal probability distribution, the odds of Genmab AS to move above the current price in 90 days from now is about 6.68 (This Genmab AS probability density function shows the probability of Genmab Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.24 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Genmab AS will likely underperform. Additionally Genmab AS has an alpha of 0.0832, implying that it can generate a 0.0832 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Genmab AS Price Density |
| Price |
Predictive Modules for Genmab AS
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Genmab AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Genmab AS Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Genmab AS is not an exception. The market had few large corrections towards the Genmab AS's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Genmab AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Genmab AS within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.08 | |
β | Beta against Dow Jones | 1.24 | |
σ | Overall volatility | 1.68 | |
Ir | Information ratio | 0.05 |
Genmab AS Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Genmab AS for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Genmab AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: CD137 Targeted Therapy Research Report 2026-2030 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global Regional Clinical Commercial Trends, |
Genmab AS Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Genmab Stock often depends not only on the future outlook of the current and potential Genmab AS's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Genmab AS's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 646.3 M | |
| Cash And Short Term Investments | 21.1 B |
Genmab AS Fundamentals Growth
Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab AS, and Genmab AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.41 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 17.38 B | ||||
| Shares Outstanding | 615.99 M | ||||
| Price To Earning | 66.53 X | ||||
| Price To Book | 3.63 X | ||||
| Price To Sales | 5.46 X | ||||
| Revenue | 21.53 B | ||||
| Gross Profit | 3.63 B | ||||
| EBITDA | 9.7 B | ||||
| Net Income | 7.84 B | ||||
| Cash And Equivalents | 21.61 B | ||||
| Cash Per Share | 33.05 X | ||||
| Total Debt | 1.03 B | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 13.11 X | ||||
| Book Value Per Share | 93.41 X | ||||
| Cash Flow From Operations | 7.77 B | ||||
| Earnings Per Share | 2.28 X | ||||
| Market Capitalization | 21 B | ||||
| Total Asset | 45.81 B | ||||
| Retained Earnings | 23.55 B | ||||
| Working Capital | 22.55 B | ||||
| Current Asset | 12.65 B | ||||
| Current Liabilities | 823.51 M | ||||
About Genmab AS Performance
By analyzing Genmab AS's fundamental ratios, stakeholders can gain valuable insights into Genmab AS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genmab AS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genmab AS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 26.42 | 25.10 | |
| Return On Tangible Assets | 0.23 | 0.24 | |
| Return On Capital Employed | 0.15 | 0.16 | |
| Return On Assets | 0.15 | 0.16 | |
| Return On Equity | 0.19 | 0.20 |
Things to note about Genmab AS performance evaluation
Checking the ongoing alerts about Genmab AS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genmab AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: CD137 Targeted Therapy Research Report 2026-2030 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global Regional Clinical Commercial Trends, |
- Analyzing Genmab AS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab AS's stock is overvalued or undervalued compared to its peers.
- Examining Genmab AS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genmab AS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab AS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genmab AS's stock. These opinions can provide insight into Genmab AS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |